Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, Fabjan TH, Fazekas F, Fuchs S, Havrdova E, Ledinek AH, Illes Z, Jazbec SS, Klimova E, Komoly S, Kurca E, Linnebank M, Lisy L, Mares J, Prochazkova L, Csilla R, Szilasiova J, Stourac P, Talab R, Turcani P, Vachova M, Vecsei L, Vodusek D, Zapletalova O, Berger T.

CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101.

PMID:
23607697
2.

Sustained-release fampridine for symptomatic treatment of multiple sclerosis.

Korenke AR, Rivey MP, Allington DR.

Ann Pharmacother. 2008 Oct;42(10):1458-65. doi: 10.1345/aph.1L028. Epub 2008 Sep 9. Review.

PMID:
18780812
3.

Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.

Fernandez O, Berger T, Hartung HP, Putzki N.

Expert Rev Clin Pharmacol. 2012 Nov;5(6):649-65. doi: 10.1586/ecp.12.59. Epub 2012 Nov 13.

PMID:
23146002
4.

Sustained release oral fampridine in the treatment of multiple sclerosis.

Kachuck NJ.

Expert Opin Pharmacother. 2009 Aug;10(12):2025-35. doi: 10.1517/14656560903075994. Review. Erratum in: Expert Opin Pharmacother. 2009 Oct;10(14):2393.

PMID:
19586420
5.

Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.

Mathiesen HK, Sorensen PS.

Expert Rev Neurother. 2013 Dec;13(12):1309-17. doi: 10.1586/14737175.2013.859523. Review.

PMID:
24236901
6.

[4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Husseini L, Leussink VI, Kieseier BC, Hartung HP.

Nervenarzt. 2010 Feb;81(2):203-11. doi: 10.1007/s00115-009-2902-2. Review. German.

PMID:
20112006
7.

Sustained-release fampridine for multiple sclerosis.

Bever CT, Judge SI.

Expert Opin Investig Drugs. 2009 Jul;18(7):1013-24. doi: 10.1517/13543780903002082. Review. Erratum in: Expert Opin Investig Drugs. 2009 Aug;18(8):1241.

PMID:
19548855
8.

Fampridine-SR for multiple sclerosis and spinal cord injury.

Hayes KC.

Expert Rev Neurother. 2007 May;7(5):453-61. Review.

PMID:
17492896
9.

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.

Cornblath DR, Bienen EJ, Blight AR.

Clin Ther. 2012 May;34(5):1056-69. doi: 10.1016/j.clinthera.2012.03.007. Epub 2012 Apr 11. Review.

PMID:
22497693
10.

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.

Dunn J, Blight A.

Curr Med Res Opin. 2011 Jul;27(7):1415-23. doi: 10.1185/03007995.2011.583229. Epub 2011 May 20. Review.

PMID:
21595605
11.

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators..

Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.

PMID:
19249634
12.

Dalfampridine in multiple sclerosis.

Goodman AD, Hyland M.

Drugs Today (Barc). 2010 Sep;46(9):635-9. doi: 10.1358/dot.2010.46.9.1499027. Review.

PMID:
20967295
13.

[Fampridine and multiple sclerosis].

Mathiesen HK, Sørensen PS.

Ugeskr Laeger. 2014 Jan 13;176(3A):V06130416. Review. Danish.

PMID:
25347174
14.

Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.

Filli L, Zörner B, Kapitza S, Reuter K, Lörincz L, Weller D, Sutter T, Killeen T, Gruber P, Petersen JA, Weller M, Linnebank M.

Neurology. 2017 Feb 28;88(9):832-841. doi: 10.1212/WNL.0000000000003656. Epub 2017 Feb 1.

PMID:
28148629
15.

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.

Blight AR, Henney HR 3rd, Cohen R.

Ann N Y Acad Sci. 2014 Nov;1329:33-44. doi: 10.1111/nyas.12512. Epub 2014 Aug 25. Review.

16.

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.

Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J.

Mult Scler. 2016 Feb;22(2):212-21. doi: 10.1177/1352458515581436. Epub 2015 Apr 28.

17.

Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.

Fragoso YD, Adoni T, Alves-Leon SV, Apostolos-Pereira SL, Barreira AA, Brooks JB, Claudino R, Correa EC, Ferreira ML, Finkelsztejn A, Finkelsztejn J, da Gama PD, Goncalves MV, Guerreiro CT, da Cunha Matta AP, Marques VD, Rizo Morales R, Parolin MF, de Castro Ribeiro M, Ribeiro TA, Ruocco HH, Sato H, Scherpenhuijzen S, Siquineli F, de Carvalho Sousa NA, Varela DL, Tauil CB, Winckler TC.

NeuroRehabilitation. 2016 Jun 30;39(2):301-4. doi: 10.3233/NRE-161361.

PMID:
27372365
18.

Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.

Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A.

J Neurol Sci. 2016 Jan 15;360:102-9. doi: 10.1016/j.jns.2015.11.035. Epub 2015 Dec 2.

PMID:
26723984
19.
20.

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.

Zeller D, Reiners K, Bräuninger S, Buttmann M.

J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):707-9. doi: 10.1136/jnnp-2013-306860. Epub 2013 Dec 19. No abstract available.

Supplemental Content

Support Center